

ZKB Tracker Certificate Dynamic on HBL MedTech Equities Global Basket

23.12.2020 - Open End | Swiss Security Code 56 679 046

Summary

This Summary is to be understood as an introduction to the present Final Terms. Any investment decision in relation to the products must be based on the information contained in the Base Prospectus and in these Final Terms in their entirety and not on the Summary. In particular, each investor should consider the risk factors contained in these Final Terms and in the Base Prospectus.

The Issuer can only be held liable for the content of this Summary if the Summary is misleading, incorrect or contradictory when read together with the other parts of the Final Terms and the Base Prospectus.

Information on the securities
Type of product: ZKB Tracker Certificate Dynamic SSPA Category: Tracker Certificate (1300, acc. to the Swiss Derivative Map) ISIN: CH0566790462 Symbol: HLMT CZ Issuer: Zürcher Kantonalbank Underlying: HBL MedTech Equities Global Basket Initial Fixing Date: 18 December 2020 Settlement Date: 23 December 2020 Final Fixing Date: --- (Open End) Redemption Date: --- (Open End) Type of settlement: cash
Information concerning the offer and admission to trading
Place of the offer: Switzerland Notional Amount/Denomination/Trading Units: CHF 10'000'000.00/CHF 10.00/1 Structured Product or multiples thereof Issue price: CHF 10.00 Selling restrictions: EEA, U.S.A./U.S. persons, United Kingdom, Guernsey Information on listing: Application to list on the SIX Swiss Exchange will be filed, the first provisory trading day will be 23 December 2020

Final Terms

1. Product Description

Product Category/Name

Participation Product/Tracker Certificate (1300, according to the Swiss Derivative Map provided by the Swiss Structured Products Association)

Regulatory Notification

This product does not constitute a collective investment scheme within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA) and it is not subject to authorisation or supervision by FINMA. The issuer risk is borne by investors.

Investment Profile	<p>The composition of the Underlying of this Structured Product is managed dynamically and discretionary over the course of its term.</p> <p>The Stock selection is based on an internal model of the investment manager and is based on quantitative and qualitative criteria. The HBL MedTech Equities Global Basket focuses on shares of companies that are characterised by innovative products and services in the medical technology sector. These companies have usually built up a dominant market position over many years, which they can maintain due to high barriers to entry against competitors. Due to the increased profit and loss potential, the HBL MedTech Equities Global Basket is more suitable for risk-aware investors. By investing in a broad basket of various stocks, an optimal diversification is provided. In order to avoid unnecessary cluster risks, a maximum share of 5% per security is targeted. In addition, the HBL MedTech Equities Global Basket is regularly rebalanced to the target weighting.</p> <p>Further information about the investment strategy – if available – can be obtained free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zürich, department VRIE or by way of e-Mail address documentation@zkb.ch.</p>
Title Universe	<p>The Title Universe consists of companies which are active in the sector of medical technology. The Underlying constituents are listed at a recognized exchange (World Federation of Exchanges or FESE (Federation of European Securities Exchanges)). The current composition of the Underlying can be found under www.zkb.ch/strukturierteprodukte.</p>
Rebalancing	<p>The Investment Manager rebalances the portfolio composition based on its qualified evaluation of the market generally 12 times a year. The Investment Manager considers only Underlying Components which provide sufficient liquidity and tradability. The Rebalancing is based on net prices of the Underlying Components (average of the net prices of the Underlying Components converted into the basket currency by the Issuer). The rebalancing period may be prolonged by the Issuer due to limited tradability. The current basket composition is listed in the Annex to this termsheet.</p>
Issuer	Zürcher Kantonalbank, Zurich
Rating of the Issuer	Standard & Poor's AAA, Moody's Aaa, Fitch AAA
Lead Manager, Paying Agent, Exercise Agent and Calculation Agent	Zürcher Kantonalbank, Zurich
Investment Manager	<p>Hypothekbank Lenzburg AG (HBL), HBL Asset Management Hypothekbank Lenzburg Ltd. is a bank according to the Swiss Federal Act on Banks and Saving Institutions (BankG; SR 952.0) and a securities dealer according to the Swiss Federal Act on Securities Exchanges and Securities Trading (BEHG; SR 954.1), Hypothekbank Lenzburg Ltd. is subject to the prudential supervision of the FINMA, Laupenstrasse 27, CH-3003 Bern, http://www.finma.ch.</p> <p>The Investment Manager may not only act as distributor of the Structured Product and/or Investment Manager in relation to the Underlying but also as asset manager or financial advisor in relation to the investors in the Structured Products. This may lead to potential conflicts between the interests of the investors and the interests of the Investment Manager. The Investment Manager has taken all necessary measures to avoid such potential conflict of interest or, if such avoidance is not reasonably possible, will disclose such conflict of interest to the investors concerned.</p>
Symbol/ Swiss Security Code/ISIN	HLMTCZ/ 56 679 046/CH0566790462
Notional Amount/Denomination/ Trading Units	CHF 10'000'000.00/CHF 10.00/1 Structured Product or multiples thereof
Number of Structured Products	Up to 1'000'000, with the right to increase
Issue Price	CHF 10.00 /100.25% of Basket Value on the Initial Fixing Date
Currency	CHF

Underlying per Initial Fixing Date	Component	ISIN / Bloomberg	Related Exchange	*Currency Weight / Initial Fixing Value	Weight in %	No. of Shares/ Amount
------------------------------------	-----------	---------------------	---------------------	---	----------------	-----------------------------

Abiomed Inc	US0036541003/ ABMD UW	NASDAQ GS	USD	5.00	0.001992
			283.16247		
Align Technology Inc	US0162551016/ ALGN UW	NASDAQ	USD	4.75	0.001005
			533.01000		
Bio-Rad Laboratories Inc	US0905722072/ BIO UN	New York Stock Exchange	USD	3.75	0.000722
			585.95000		
Boditech Med Inc	KR7206640005/ 206640 KQ	Korea Stock Exchange	KRW	2.25	0.010302
			26950.00000		
CareNet Inc	JP3277550004/ 2150 JT	Tokyo	JPY	2.50	0.005264
			5520.82800		
Charm Care Corporation	JP3512740006/ 6062 JT	Tokyo	JPY	2.00	0.018155
			1280.69208		
ChemoMetec A/S	DK0060055861/ CHEMM DC	Copenhagen	DKK	4.25	0.005874
			494.74090		
CompuGroup Medical SE & Co. KGaA	DE000A288904/ COP GY	Xetra	EUR	2.50	0.003054
			75.26129		
Dexcom Inc	US2521311074/ DXCM UW	NASDAQ	USD	3.25	0.001015
			361.12000		
ELAN Corporation	JP3167680002/ 6099 JT	Tokyo	JPY	2.25	0.008646
			3025.45375		
Eurofins Scientific SE	FR0014000MR3/ ERF FP	Euronext Paris	EUR	3.25	0.004294
			69.58044		
Fisher & Paykel Healthcare Corporation Ltd	NZFAPE0001S2/ FPH NZ	New Zealand Stock Exchange	NZD	4.25	0.020185
			33.20498		
Hangzhou Tigermed Consulting Co Ltd	CNE1000040M1/ 3347 HK	Hong Kong Stock Exchange	HKD	3.75	0.019403
			169.02535		
IDEXX Laboratories Inc	US45168D1046/ IDXX UW	NASDAQ GS	USD	2.25	0.000530
			478.49000		
LifeTech Scientific Corporation	KYG548721177/ 1302 HK	Hong Kong Stock Exchange	HKD	2.25	0.500713
			3.93000		
M3 Inc	JP3435750009/ 2413 JT	Tokyo	JPY	4.00	0.004920
			9450.41735		
Medical Data Vision Co Ltd	JP3921250001/ 3902 JT	Tokyo	JPY	3.50	0.015352
			2650.39750		
Medpace Holdings Inc	US58506Q1094/ MEDP UW	NASDAQ GS	USD	2.00	0.001498
			150.59259		
MedPeer Inc.	JP3921240002/ 6095 JT	Tokyo	JPY	2.50	0.004205
			6911.03650		
Medtecs International Corp. Ltd	TW0009103002/ 9103 TT	Taiwan Stock Exchange	TWD	4.00	0.489292
			25.95000		
Mercator Medical SA	PLMRCTR00015/ MRC PW	Warsaw Stock Exchange	PLN	2.00	0.002096
			389.33839		
Pro Medicus Ltd	AU000000PME8/ PME AT	Australian Securities Exchange	AUD	4.50	0.020567
			32.49487		
Quidel Corp	US74838J1016/ QDEL UW	NASDAQ	USD	4.25	0.002428
			197.46962		
Repligen Corp	US7599161095/ RGEN UW	NASDAQ GS	USD	4.25	0.002497
			192.00880		
Revenio Group Corporation	FI0009010912/ REG1V FH	Helsinki	EUR	3.00	0.006128
			45.00675		
Simulations Plus Inc	US8292141053/ SLP UR	NASDAQ CM	USD	4.50	0.007650
			66.34995		
Staar Surgical Co	US8523123052/ STAA UQ	NASDAQ GM	USD	2.50	0.003716
			75.89138		
Universal Biotechnology Co Ltd	TW0003218004/ 3218 TT	Taiwan Stock Exchange	TWD	2.75	0.034571
			252.50000		
Veeva Systems Inc	US9224751084/ VEEV UN	New York Stock Exchange	USD	5.00	0.002008
			280.85212		
West Pharmaceutical Services Inc	US9553061055/ WST UN	New York Stock Exchange	USD	3.00	0.001237
			273.65104		

* Local taxes, transactions fees and foreign commissions are, if applicable, included in the

Initial Fixing Value of each component and are thus borne by the holders of the Structured Product. This applies particularly, though not exclusively, when exercising rights associated with the Structured Product and/or a Rebalancing.

Basket Value	CHF 9.975 on Initial Fixing Date
	The terms and conditions of the present product have been adjusted due to Corporate Actions, refer to table Corporate Actions.
Ratio	1 ZKB Tracker Certificate Dynamic represents 1 Underlying
Dividend Payments	No dividends will be paid out. The dividend as a whole will be reinvested into the Structured Product in the form of a net dividend. Payments from Korean Underlying constituents will not be considered and will not be distributed to the Structured Product.
Initial Fixing Date	18 December 2020 The Issuer has the right to expand the time period for the Initial Fixing if required by current market conditions e.g. liquidity.
Settlement Date	23 December 2020
Redemption right of the Issuer	The Issuer has the right to redeem the outstanding Structured Products quarterly on the 15th day of March, June, September and December (fixing date; modified following), for the first time on 15 December 2021. On the fixing date, the redemption amount is determined, which is governed by the information under the section Redemption Method. The Issuer has the right to expand the time period for the Final Fixing if required by current market conditions e.g. liquidity. The announcement and thus the declaration of intent to exercise the Redemption right is made with a notice period of 20 banking days via the official publication channel of the SIX Swiss Exchange. No statement of reasons is required. The redemption will be executed with a value date of 5 bank working days after the fixing date (Redemption Date).
Right to return of the Investor	In addition to the possibility of selling the Structured Products in the secondary market, the investor has the right to return the product quarterly per 15th day of the months March, June, September and December (fixing date; modified following) to the Issuer, for the first time on 15 December 2021. On the fixing date, the redemption amount is determined, which is governed by the information under the section Redemption Method. The Issuer has the right to expand the time period for the Final Fixing if required by current market conditions e.g. liquidity. The declaration of intent to exercise the Right to return must be received no later than 5 banking days before the respective fixing date (exercise date) by Zürcher Kantonalbank and must be sent to the following address: by letter post to Zürcher Kantonalbank, Sales Structured Products, IHHV, P.O. Box, 8010 Zürich or by email to derivate@zkb.ch . The repayment will be executed with a value date of 5 bank working days after the fixing date (Redemption Date). Should the Structured Products of the Investor be deposited in a custodian bank, the Investor needs additionally and in due time advise/inform his custodian bank according the notice of redemption.
Initial Fixing Level	18 December 2020, Net price of the Components of the Underlying on a best effort basis.
Redemption Method	On Redemption Date, investors receive in cash for every certificate 100% of the Underlying as defined on the Final Fixing Date and according to the following formula: $\text{Ratio} * \left(\sum_{i=1}^N S_{i,T} * W_{i,T} * FX_{i,T} \right) - \text{Fees}$ where Ratio = 1 $S_{i,T}$ = Value of the Component i of the Underlying on Final Fixing Date $W_{i,T}$ = Weighting of the Component i of the Underlying (number of Shares) on Final Fixing Date Fees = Annual Fee and Rebalancing Fees $FX_{i,T}$ = Exchange rate of the Component i of the Underlying (to CHF) on Final Fixing Date T = Final Fixing Date
	If capital events that were unknown at the time of issue take place during the life of the ZKB Tracker Certificate Dynamic, they shall be taken into account by adjusting the weighting of the affected Component of the Underlying accordingly.
Listing	Application to list on the SIX Swiss Exchange will be filed, the first provisory trading day will be 23 December 2020.

Annual Fee	1.10% p.a. The Annual Fee will be charged based on the value of the Structured Product and is pro rata temporis included in the trading price. Of the Annual Fee, the Issuer receives 0.30% p.a. and the Investment Manager receives 0.80% p.a. for their relevant duties.	
Rebalancing Fee	Rebalancings exceeding 15 per year will be charged with a Rebalancing Fee of 0.10% of the transaction value	
Clearing House	SIX SIS AG/Euroclear/Clearstream	
Distribution fees	No distribution fees in the form of a discount on issue price, reimbursement of a part of the issue price or other one-off and/or periodic charges are paid out to one or several distribution partners of this Structured Product.	
Sales: 044 293 66 65	SIX Telekurs: .zkb Internet: www.zkb.ch/finanzinformationen	Reuters: ZKBSTRUCT Bloomberg: ZKBY <go>
Key Elements of the Product	In terms of value, buying a ZKB Tracker Certificate Dynamic is equivalent to buying the Underlying less any Fees. A single, low-cost transaction gives investors the opportunity to participate fully in the performance of the Underlying. Dividend Payments of underlying components in the basket are paid out to the investor by means of Dividend reinvestment in the Underlying. Redemption is based on the weighted value of Underlying components on the Fixing Date.	
Taxes	<p>The Issuer reports the taxable factors (change to previous year's value) divided in the components income and capital gain to the Swiss Federal Tax Administration on 31 October each year. The income part is subject to Swiss income tax for private investors with Swiss tax domicile as per reporting date. The capital gain part is not subject to Swiss income tax. The product is not subject to Swiss withholding tax. The Federal securities transfer stamp tax is not levied on secondary market transactions. This product may be subject to additional withholding taxes or duties, such as related to FATCA, Sect. 871(m) U.S. Tax Code or foreign financial transaction taxes. Any payments due under this product are net of such taxes or duties.</p> <p>The information above is a summary only of the Issuer's understanding of current law and practice in Switzerland relating to the taxation of Structured Products. The relevant tax law and practice may change. The Issuer does not assume any liability in connection with the above information. The tax information only provides a general overview and can not substitute the personal tax advice to the investor.</p>	

Documentation

This document is a non-binding English translation of the Final Terms (Endgültige Bedingungen) published in German and constituting the Final Terms in accordance with article 45 of the Federal Act on Financial Services (FinSA). The English language translation is provided for convenience only.

The binding German version of these Final Terms supplements the Base Prospectus approved by the SIX Exchange Regulation Ltd and published in German by the Issuer on 16 November 2020. These Final Terms constitute a Simplified prospectus pursuant to article 5 para. 2 CISA in the version dated 1 March 2013. Together with the Base Prospectus (and together with any supplements) these Final Terms form the product documentation for this issue.

If this Product was the first time issued under the Base Prospectus of 16 November 2020, these Final Terms must be read in conjunction with the General Terms of the Securities (Allgemeine Bedingungen der Derivate), the Additional Terms and the Information on the Underlyings in the Base Prospectus of 16 November 2020. If this Product has been issued prior to the date of the Base Prospectus of 16 November 2020, these Final Terms shall be read in conjunction with the Base Prospectus of 16 November 2020 and together with the Existing Terms of the Products from the version of the Issuance Programme or Base Prospectus in force at the time of issuance that has been incorporated by reference in this Base Prospectus.

The Base Prospectus of the Issuer dated 16 November 2020 will cease to be valid on 16 November 2021. From and including this date, these Final Terms must be read together with the latest valid version of the Base Prospectus of the Issuer (including the information incorporated by reference into the latest valid version of the Base Prospectus from the Base Prospectus under which the Products the first time were issued), which follows the Base Prospectus of 16 November 2020.

Except as otherwise defined in these Final Terms, the terms used in these Final Terms have the meaning given to them in the Base Prospectus. In case of discrepancies between information or the provisions in these Final Terms and those in the Base Prospectus, the information and provisions in these Final Terms shall prevail. In the event of a listing of the products, the product documentation will be adapted, if and to the extent necessary, in accordance with the requirements of the relevant exchange. The present products will be issued in the form of uncertificated securities (Wertrechte) and registered as book-entry securities (Bucheffekten) with SIX SIS AG. Investors have no right to require the issuance of any certificates or any proof of evidence for the products.

These Final Terms and the Base Prospectus can be ordered free of charge at Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, dept. VRIE or by e-mail at documentation@zkb.ch. They are also available on <https://www.zkb.ch/finanzinformationen>.

Information on the Underlying

Information on the performance of the Underlying/a component of the Underlying is publicly available on www.bloomberg.com. Current annual reports are published on the website of the respective business entity. The transfer of the Underlying/a component of the Underlying is conducted in accordance with their respective statutes.

Notices

Any notice by the Issuer in connection with these Structured Products, in particular any notice in connection with modifications of the terms and conditions will be validly published on the website <https://www.zkb.ch/finanzinformationen> under the relevant Structured Product. The Swiss security code search button will lead you directly to the relevant Structured Product. The notices will be published in accordance with the rules issued by SIX Swiss Exchange for IBL (Internet Based Listing) on the website <https://www.six-exchange-regulation.com/en/home/publications/official-notices.html>

Governing Law/Jurisdiction

Swiss Law/Zurich

2. Profit and Loss Expectations after Year 1

Profit and Loss Expectations after Year 1

ZKB Tracker Certificate Dynamic

Basket		Redemption	
Value	Percent	ZKB Tracker Certificate Dynamic	Performance %
CHF 8.48	-15.00%	CHF 8.39	-16.15%
CHF 8.98	-10.00%	CHF 8.88	-11.21%
CHF 9.48	-5.00%	CHF 9.37	-6.28%
CHF 10.00	+0.25%	CHF 9.89	-1.10%
CHF 10.47	+5.00%	CHF 10.36	3.59%
CHF 10.97	+10.00%	CHF 10.85	8.52%
CHF 11.47	+15.00%	CHF 11.35	13.45%

Source: Zürcher Kantonalbank

The performance of the ZKB Tracker Certificate Dynamic is analog to the performance of the Underlying less any Fees. Rebalancing Fees are not included in the table above.

The figures in the table above are valid after Year 1 only and cannot be considered as a price indication for the present Structured Product during its lifetime. The price quoted in the secondary market can differ substantially from the table above.

3. Material Risks for Investors

Credit Risk Relating to Issuer

Obligations under these Structured Products constitute direct, unconditional and unsecured obligations of the Issuer and rank pari passu with other direct, unconditional and unsecured obligations of the Issuer. The value of the Structured Product does not only depend on the performance of the Underlying and other developments in the financial markets, but also on the solvency of the Issuer, which may change during the term of this Structured Product.

Specific Product Risks

Structured Products are complex financial instruments, which entail considerable risks and, accordingly, are only suitable for investors who have the requisite knowledge and experience and understand thoroughly the risks connected with an investment in these structured products and are capable of bearing the economic risks.

ZKB Tracker Certificate Dynamic is an investment product whose price fluctuates to the same degree as the Underlying less any Fees. Depending on price trends, the price of a ZKB Tracker Certificate Dynamic could fall below the Issue Price. The risk profile of the ZKB Tracker Certificate Dynamic corresponds to that of the Underlying. The ZKB Tracker Certificate Dynamic is denominated in CHF. The investor bears all the risks in connection with a possible exchange rate risk between the product currency, the currency of the components of the Underlying, and his reference currency.

Investments with regard to Emerging Markets are exposed to several risk factors especially political or economic risks. The political system, the continuity and the political culture of emerging markets might be totally different compared to developed countries and might therefore cause a negative influence on the Underlying and/or the currencies. The relevant Underlyings and currencies are generally not as liquid as those of developed countries. Purchase and sales might cause market fluctuations. Especially in emerging markets currency transfer restrictions and/or a connectivity to a reference currency are more likely.

4. Additional Terms

Modifications

If an extraordinary event as described in the Base Prospectus occurs in relation to the Underlying/a component of the Underlying or if any other extraordinary event occurs, which makes it impossible or particularly cumbersome for the Issuer, to fulfill its obligations under the Products or to calculate the value of the Products, the Issuer shall at its own discretion take all the necessary actions and, if necessary may modify the terms and conditions of these Products at its own discretion in such way, that the economic value of the Products after occurrence of the extraordinary event corresponds, to the extent possible, to the economic value of the Products prior to the occurrence of the extraordinary event. Specific modification rules for certain types of Underlyings stated in the Base Prospectus shall prevail. If the Issuer determines, for whatever reason, that an adequate modification is not possible, the Issuer has the right to redeem the Products early.

Market Disruptions

Compare specific provisions in the Base Prospectus.

Substitution of Underlying	During the term of the Structured Product, changes in or substitution of the Underlying by the Calculation Agent can occur. In this case, it cannot be ruled out that such changes or substitutions will negatively affect the value of the Structured Product. Likewise, it cannot be ruled out that in the case of a Structured Product based on an index that changes in the composition of the index as a result of change or substitutions in respect of individual index components, for example, as a result of the withdrawal or addition of individual securities, may negatively influence the price of the index and accordingly the value of the Structured Product.
Selling Restrictions	EEA, U.S.A./U.S. persons, United Kingdom, Guernsey
Prudential Supervision	As a bank within the meaning of the Swiss Federal Act on Banks and Savings Banks (BankG; SR 952.0) and a securities firm within the meaning of the Swiss Federal Act on Financial Institutions (FinlAG; SR 954.1), Zürcher Kantonalbank is subject to the prudential supervision of FINMA, Laupenstrasse 27, CH-3003 Bern, https://www.finma.ch .
Recording of Telephone Conversations	Investors are reminded that telephone conversations with trading or sales units of Zürcher Kantonalbank are recorded. Investors, engaging in telephone conversations with these units provide their tacit consent to the recording of their conversations.
Further Information	This document constitutes neither an offer nor a recommendation or invitation to purchase financial instruments and can't replace the individual investor's own judgement. The information contained in this document does not constitute investment advice but is intended solely as a product description. An investment decision should in any case be made on the basis of these Final Terms and the Base Prospectus. Particularly, before entering into a transaction, the investor should, if necessary with the assistance of an advisor, examine the conditions for investment in the Product in consideration of his personal situation with regard to legal, regulatory, tax and other consequences. Only an investor who is aware of the risks of the transaction and has the financial capacity to bear any losses should enter into such transactions.
Material Changes	Since the end of the last financial year or the date of the interim financial statements, there have been no material changes in the assets, financial or revenue position of the Issuer.
Responsibility for the Final Terms	Zürcher Kantonalbank, Zurich, assumes responsibility for the content of these Final Terms and hereby declares that, to its knowledge, the information contained in these Final Terms is correct and no material circumstances have been omitted.

Zurich, 18 December 2020, last update on 10 February 2021

Underlying on 10 02 2021

Component	ISIN / Bloomberg	Related Exchange	*Currency / Initial Fixing Value	Weight in %	No. of Shares/ Amount
Abiomed Inc	US0036541003/ ABMD UW	NASDAQ GS	324.3827	5.00	0.001910
Align Technology Inc	US0162551016/ ALGN UW	NASDAQ	614.8155	4.75	0.000957
Bio-Rad Laboratories Inc	US0905722072/ BIO UN	New York Stock Exchange	649.3711	3.78	0.000722
Boditech Med Inc	KR7206640005/ 206640 KQ	Korea Stock Exchange	19503.1669	2.25	0.015804
CareNet Inc	JP3277550004/ 2150 JT	Tokyo	4613.5278	2.50	0.007022
Charm Care Corporation	JP3512740006/ 6062 JT	Tokyo	1339.0000	1.88	0.018155
ChemoMetec A/S	DK0060055861/ CHEMM DC	Copenhagen	613.8158	4.25	0.005262
Cash CHF	CH0002748082/ CHF	other	1.0000	0.53	0.058348
CompuGroup Medical SE & Co. KGaA	DE000A288904/ COP GY	Xetra	79.0500	2.36	0.003054
Dexcom Inc	US2521311074/ DXCM UW	NASDAQ	401.0929	3.29	0.001015
ELAN Corporation	JP3167680002/ 6099 JT	Tokyo	1494.9737	2.25	0.019503
Eurofins Scientific SE	FR0014000MR3/ ERF FP	Euronext Paris	80.4600	3.38	0.004294
Fisher & Paykel Healthcare Corporation Ltd	NZFAPE0001S2/ FPH NZ	New Zealand Stock Exchange	32.8236	4.25	0.022188
Hangzhou Tigermed Consulting Co Ltd	CNE1000040M1/ 3347 HK	Hong Kong Stock Exchange	183.0000	3.70	0.019403
IDEXX Laboratories Inc	US45168D1046/ IDXX UW	NASDAQ GS	502.6254	2.15	0.000530
LifeTech Scientific Corporation	KYG548721177/ 1302 HK	Hong Kong Stock Exchange	4.8832	2.25	0.442643
M3 Inc	JP3435750009/ 2413 JT	Tokyo	8688.6177	4.00	0.005966
Medical Data Vision Co Ltd	JP3921250001/ 3902 JT	Tokyo	2348.9089	3.50	0.019309
Medpace Holdings Inc	US58506Q1094/ MEDP UW	NASDAQ GS	155.3636	1.88	0.001498
MedPeer Inc.	JP3921240002/ 6095 JT	Tokyo	7490.0000	2.43	0.004205
Medtecs International Corp. Ltd	TW0009103002/ 9103 TT	Taiwan Stock Exchange	26.1500	4.00	0.531072
Mercator Medical SA	PLMRCTR00015/ MRC PW	Warsaw Stock Exchange	350.1050	2.00	0.002612
Pro Medicus Ltd	AU000000PME8/ PME AT	Australian Securities Exchange	43.7954	4.50	0.016454
Quidel Corp	US74838J1016/ QDEL UW	NASDAQ	236.3091	4.25	0.002229
Repligen Corp	US7599161095/ RGEN UW	NASDAQ GS	215.6276	4.35	0.002497
Revenio Group Corporation	FI0009010912/ REG1V FH	Helsinki	53.2840	3.00	0.005753
Simulations Plus Inc	US8292141053/ SLP UR	NASDAQ CM	89.4931	4.50	0.006231
Staar Surgical Co	US8523123052/ STAA UQ	NASDAQ GM	124.1228	2.50	0.002496
Universal Biotechnology Co Ltd	TW0003218004/ 3218 TT	Taiwan Stock Exchange	226.0000	2.75	0.042246
Veeva Systems Inc	US9224751084/ VEEV UN	New York Stock Exchange	302.2307	4.90	0.002008
West	US9553061055/ West	New York Stock	288.8791	2.88	0.001237

Pharmaceutical
Services Inc

WST UN

Exchange

* Local taxes, transactions fees and foreign commissions are, if applicable, included in the Initial Fixing Value of each component and are thus borne by the holders of the Structured Product. This applies particularly, though not exclusively, when exercising rights associated with the Structured Product and/or a Rebalancing.

Corporate Actions

Date	Underlying	Action		
29.12.2020	ELAN Corporation	Stock Split on 29.12.2020	No. of Shares old 0.008677	No. of Shares new 0.017354
29.12.2020	ELAN Corporation	Stock Split on 29.12.2020	Initial Fixing Value old 3025.45375	Initial Fixing Value new 1512.73
		Rebalancing on 10.02.2021	Amount old	Amount new
10.02.2021	Abiomed Inc	Rebalancing	0.001992	0.001910
10.02.2021	Align Technology Inc	Rebalancing	0.001005	0.000957
10.02.2021	Boditech Med Inc	Rebalancing	0.010302	0.015804
10.02.2021	CareNet Inc	Rebalancing	0.005264	0.007022
10.02.2021	Cash CHF	Buy	-	0.058348
10.02.2021	ChemoMetec A/S	Rebalancing	0.005874	0.005262
10.02.2021	ELAN Corporation	Rebalancing	0.017354	0.019503
10.02.2021	Fisher & Paykel Healthcare Corporation Ltd	Rebalancing	0.020185	0.022188
10.02.2021	LifeTech Scientific Corporation	Rebalancing	0.500713	0.442643
10.02.2021	M3 Inc	Rebalancing	0.004920	0.005966
10.02.2021	Medical Data Vision Co Ltd	Rebalancing	0.015352	0.019309
10.02.2021	Medtecs International Corp. Ltd	Rebalancing	0.489292	0.531072
10.02.2021	Mercator Medical SA	Rebalancing	0.002096	0.002612
10.02.2021	Pro Medicus Ltd	Rebalancing	0.020567	0.016454
10.02.2021	Quidel Corp	Rebalancing	0.002428	0.002229
10.02.2021	Revenio Group Corporation	Rebalancing	0.006128	0.005753
10.02.2021	Simulations Plus Inc	Rebalancing	0.007650	0.006231
10.02.2021	Staar Surgical Co	Rebalancing	0.003716	0.002496
10.02.2021	Universal Biotechnology Co Ltd	Rebalancing	0.034571	0.042246